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The orchestration of brain function requires complex
gene regulatory networks that aremodulated, in part,
by microRNAs (miRNAs). These noncoding RNAs
associate with argonaute (Ago) proteins in order
to direct posttranscriptional gene suppression via
base pairing with target transcripts. In order to bet-
ter understand how miRNAs contribute to human-
specialized brain processes and neurological
phenotypes, identifying their targets is of paramount
importance. Here, we address the latter by profiling
Ago2:RNA interactions using HITS-CLIP to generate
a transcriptome-wide map of miRNA binding sites
in human brain. We uncovered 7,000 stringent
Ago2 binding sites that are highly enriched for
conserved sequences corresponding to abundant
brain miRNAs. This interactome points to functional
miRNA:target pairs across >3,000 genes and re-
presents a valuable resource for accelerating our
understanding of miRNA functions in brain. We
demonstrate the utility of this map for exploring
clinically relevant miRNA binding sites that may facil-
itate the translation of genetic studies of complex
neuropsychiatric diseases into therapeutics.
INTRODUCTION
During the past decade, microRNAs (miRNAs; 19–22 nucleo-
tides) have emerged as key posttranscriptional regulators of
gene expression, having been implicated in nearly all biological
processes (Krol et al., 2010). In brain, miRNAs play vital roles in
cell-fate specification, neurite projection, and synaptic plasticity,
and growing evidence suggests that even slight aberrations in
miRNA activities can be detrimental to neuronal function (Im
and Kenny, 2012). The human genome encodes nearly 2,000
unique miRNAs, some being highly conserved across species,294 Neuron 81, 294–305, January 22, 2014 ª2014 Elsevier Inc.and others being specific to primate or human lineages. miRNAs
are excised from larger stem-loop-containing transcripts and
are subsequently incorporated into argonaute (Ago) proteins.
This generates functional entities capable of silencing target
transcripts via translational repression and mRNA destabiliza-
tion (Bazzini et al., 2012; Djuranovic et al., 2012). miRNAs typi-
cally bind to target mRNA 30 UTRs containing short stretches
of complementarity to the ‘‘seed’’ region of the miRNA, corre-
sponding to positions 2–8 (Lewis et al., 2005). Although this
minimal degree of base pairing provides attractive means
for miRNAs to coordinate cellular responses by regulating
numerous transcripts within common pathways, this poses
a significant challenge for elucidating biologically relevant
miRNA:target interactions by bioinformatic prediction, an
important and common first step toward target identification.
Bioinformatic approaches tend to overpredict miRNA binding
sites, supporting the need for complementary wet lab data to
assist with identifying bona fide interactions. Transcriptional
and proteomic profiling studies have aided the search for func-
tional miRNA target sites; however, these approaches are unable
to discern whether observed changes in gene expression are the
result of direct miRNA:target interactions. To address this,
recent work has focused on using high-throughput methods
(e.g., high-throughput sequencing of RNA isolated by cross-
linking immunoprecipitation [HITS-CLIP], CLIP sequencing
[CLIP-seq], photoactivatable ribonucleoside-enhanced CLIP
[PAR-CLIP], and crosslinking, ligation, and sequencing of
hybrids [CLASH]) (Chi et al., 2009; Hafner et al., 2010; Helwak
et al., 2013; Leung et al., 2011; Zisoulis et al., 2010) to biochem-
ically determine Ago:miRNA binding sites on a transcriptome-
wide scale. These approaches involve crosslinking RNA binding
proteins with RNAs, immunoprecipitating Ago proteins, and
sequencing the associated RNAs. Ago proteins (namely, Ago1
and Ago2) are the core components of miRNA-silencing com-
plexes (Krol et al., 2010), and this powerful technique allows
for sequencing of both themiRNAs and themRNA target regions
towhich they bind. Inmice, these approaches have been applied
in brain and liver tissues (Chi et al., 2009; Schug et al., 2013);
however, human data are only available for cultured cells (Chi
et al., 2009; Haecker et al., 2012; Hafner et al., 2010). In order
Figure 1. Workflow for Performing Ago2 HITS-CLIP in Human Brain
(A) Illustration depicting the regions from which gray matter samples were harvested from human postmortem brains and initial tissue processing steps.
(B) Western blot showing immunoprecipitation efficiency of human Ago2 (94 kDa) from postmortem brain samples.
(C) Autoradiography of 32P-labeled RNA:protein complexes resolved by SDS-PAGE after Ago2 CLIP shows the expected doublet corresponding to the indicated
complexes. IgG immunoprecipitation serves as the negative control.
(D) Diagram depicting the workflow for processing high-throughput sequencing data in order to obtain miRNA read information and Ago2 brain clusters. The
average number of reads per sample at each filtering step is provided.
(E) Pie chart showing the relative abundance of miRNA reads (grouped into families on the basis of shared seed sequence) for all samples.
(F) UCSC Genome Browser images of positional read coverage for each of the 11 samples (S1–S11) illustrate reproducibility across samples. Images span the
30 UTRs of the indicated genes, covering > 6,400 nt in total per sample.
See also Figures S1 and S2 and Tables S1–S3.
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Mapping miRNA Binding Sites in Human Brainto advance our understanding of miRNA functions in humans,
miRNA:target interactions must be further queried in primary
tissues. Here, seeking to gain insight into the array of transcripts
engaged with miRNAs in human brain, we profiled transcrip-
tome-wide Ago2:RNA interactions in human brain tissues using
HITS-CLIP (i.e., CLIP-seq) methodology.
RESULTS
Ago2 HITS-CLIP Yields miRNAs and Their
Transcriptomic Target Sites in Human Brain Samples
We performed Ago2 HITS-CLIP on a panel of 11 postmortem
human brain samples harvested from adult motor cortex and
cingulate gyrus—regions associated with movement and psy-chiatric disorders (all brain tissues were obtained from males
ranging from ages 44–68; Figure 1A; Table S1 available online).
Initial analyses confirmed the specific immunoprecipitation of
Ago2 bound to radiolabeled cellular RNAs (Figures 1B and 1C).
Notably, gel electrophoresis coupled with autoradiography
revealed the previously described doublet (Chi et al., 2009), rep-
resenting Ago2 complexed with miRNAs (lower band) and Ago2
complexed with miRNAs and target RNA tags (upper band).
Cloning and high-throughput sequencing of these Ago2-associ-
ated RNAs produced nearly 50 million reads for each sample,
yielding an average of 200,000 reads mapping to known human
mature miRNAs (miRBase) and 15 million uniquely mapped
reads within the human genome (Figure 1D). Upon the
removal of PCR duplicates on the basis of redundant genomicNeuron 81, 294–305, January 22, 2014 ª2014 Elsevier Inc. 295
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Mapping miRNA Binding Sites in Human Braincoordinates, each sample generated roughly 1 million uniquely
mapped reads, providing considerable depth for HITS-CLIP
analysis.
Reads mapping to mature miRNAs were reproducible across
samples (median R2 = 0.79 for all pairwise comparisons; Fig-
ure S1A), particularly among the most highly expressed miRNAs
(Figure S1B). In total, we detected nearly 1,900 unique miRNAs
(Table S2), including an abundance of known brain-enriched
miRNAs that were present at relative levels comparable to previ-
ous studies profiling human brain miRNAs by small RNA
sequencing and microarray (Hu et al., 2011; Shao et al., 2010).
When miRNA read counts were grouped into their respective
seed families, the top five most abundant Ago2-associated
seed sequences (Let-7, miR-125, miR-124, miR-9, and miR-29)
comprised nearly 55% of total Ago2 ‘‘seed load’’ present in the
samples (Figures 1E and S1B), and the top 20 seeds accounted
for 75%. These data are consistent with prior reports citing that
highly abundant miRNAs often constitute the vast majority of
cellular miRNA pools and are generally the chief miRNAs medi-
ating significant target suppression within cells (Chi et al.,
2009; Hafner et al., 2010; Mullokandov et al., 2012).
Unique reads not mapping to known miRNAs were subjected
to peak-calling in order to identify Ago2 binding sites (i.e.,
clusters; see the Experimental Procedures) within Ensembl-
annotated genes. In brief, we calculated the significance of
enrichment for overlapping reads at each genomic position
relative to the nearby context and summarized the positional
p values across all 11 samples. Positions having a combined
Bonferroni adjusted p value < 5% were used for downstream
cluster formation, which involved merging nearby coordinates
(within 60 nt) and extending all remaining positions to 50 nt in
order to account for the Ago2 binding footprint (Chi et al.,
2009). This peak-calling strategy resulted in the identification
of 7,153 high-confidence human Ago2 brain clusters (Bonfer-
roni adjusted p value < 5%) associating with >3,300 brain-
expressed genes (Table S3). We gauged the overall resolution
of the Ago2 binding sites by evaluating cluster length distribu-
tions. Notably, >80% of the clusters are %60 nt in length, and
only 6% are >100 nt (Table S3). Pairwise correlations of the
positional read counts (i.e., wiggle files) for each sample sup-
ported moderate to high reproducibility of mapped reads (Fig-
ure S2A; median R2 = 0.80). Furthermore, data consistency
among samples was visually evident across many genes, as
observed in the University of California Santa Cruz (UCSC)
Genome Browser (Figures 1F and S2B). As with previous
CLIP-based studies, we observed an inherent bias toward
identifying Ago2 binding sites in higher-expressed transcripts
(data not shown); on average, our studies ascertained roughly
two sites per target gene.
Characterization of Ago2 Binding Sites in Human Brain
Next, we characterized the human Ago2 brain clusters. First,
we analyzed cluster sequence content by performing unbiased
motif enrichment analyses to evaluate the relationship between
human Ago2 brain clusters and miRNAs present in the sam-
ples. Among the most significantly enriched motifs were
sequences corresponding to the top five most abundant
miRNA seeds, including 7A1 (reverse complement of miRNA296 Neuron 81, 294–305, January 22, 2014 ª2014 Elsevier Inc.positions 2–7 followed by an adenine base), 7m8 (reverse com-
plement of miRNA positions 2–8), and some noncanonical seed
types (e.g., 7m9 [reverse complement of miRNA positions 3–9]
and seeds containing G:U wobble pairing or bulged mis-
matches) (Chi et al., 2012) (Figure 2A and Table S4). Heptamers
corresponding to other fairly abundant miRNA seeds were also
significantly enriched. Notably, highly enriched miRNA seed
motifs showed a positional bias to the immediate right of clus-
ter centers; this corresponds to the expected position of seed
sites engaged in reverse complement target recognition and
is consistent with data from previous Ago PAR-CLIP studies
(Hafner et al., 2010) (Figure 2B). We also performed positional
analyses with respect to the miRNAs themselves and found
that the enrichment of motifs corresponding to miRNA se-
quences was primarily constrained to seed regions (Figure S3).
In some instances, evidence for significant 30 compensatory
binding was observed (e.g., miR-125-5p and miR-124-3p),
whereas other miRNAs showed evidence for shifted binding
(miR-103-3p and miR-221-3p). Notably, the latter is not likely
the result of miRNA processing heterogeneity, given that the
vast majority of small RNA reads mapping to these miRNA
stem loops correspond to the annotated mature miRNA
(>85%) (data not shown). Furthermore, shifted binding by
miR-221 was previously observed in a recent study employing
the CLIP-based technique known as CLASH, an advanced
approach for identifying noncanonical miRNA binding sites
(Helwak et al., 2013).
We also performed a biased approach to determine the com-
bined enrichment of 7A1 and 7m8 sites for each known miRNA
seed sequence (Figure 2C and Table S5). Sites corresponding
to 15 of the top 20 most abundant miRNA seeds were signifi-
cantly enriched (false discovery rate [FDR] < 5%), and a general
diminishing enrichment among the remaining seeds by rank
(e.g., groups 21–40 and 41–60 by ranked seed abundance; Fig-
ure 2D) was evident. Notably, significantly enriched motifs
among these lesser abundant seeds include those correspond-
ing tomiRNAs previously described as brain-enriched (e.g., miR-
101,miR-153, andmiR-485) or having synaptic (e.g., miR-138) or
glial (e.g., miR-23) localization (Cohen et al., 2011; Farh et al.,
2005; Lagos-Quintana et al., 2002; Sempere et al., 2004; Siegel
et al., 2009; Smirnova et al., 2005), signifying functionality in brain
despite moderate-to-lower expression levels.
Second, the intragenic locations of clusters were determined
on the basis of Ensembl gene annotations, and 97% resided
within mRNA transcripts. The largest proportions of clusters
are present in 30 UTRs and coding regions (41% and 40%,
respectively) (Figure 3A). Analogous to the mouse brain Ago
HITS-CLIP data (Chi et al., 2009), we observed a positional
bias for Ago2 binding sites to be enriched at the 50 and 30 ends
of 30 UTRs (Figure 3B), regions associated with increasedmiRNA
functionality (Grimson et al., 2007). Furthermore, >25% of the
Ago2 brain clusters in 30 UTRs overlap with TargetScan-
predicted conserved miRNA binding sites (>2-fold enrichment
over background expectations, Pearson’s chi-square test p <
2.23 1016; Table S3) (Grimson et al., 2007). Overall, Ago2 brain
clusters showed increased conservation (PhastCon scores) rela-
tive to flanking genomic regions (Figure 3C), lending additional
support to site functionality.
Figure 2. Characterization of Human Ago2
Brain Cluster Sequences
(A) Analysis of cluster sequences with RSAT (peak
motifs tool) identified significant enrichment of
motifs corresponding to abundant brain miRNAs
(logos shown).
(B) Graph summarizing the positional enrichment
of motifs identified by RSAT run on Ago2 brain
cluster sequences. The enriched motifs corre-
sponding to abundant brainmiRNAs are located to
the right of center, which is consistent with miRNA
target recognition via reverse complementary
Watson-Crick base pairing, as illustrated above.
(C) The relative combined enrichment of 7A1 and
7m8 sites corresponding to the top 20 most
abundant miRNA seeds is shown. The significance
of enrichment (Ago2 clusters versus background;
FDR) is indicated by color key and symbol.
(D) The positional seed counts within and near
Ago2 brain clusters (centered on zero, median
cluster size is 51 nt) are shown for the indicated
miRNA seeds grouped by abundance rank.
See also Figures S3 and S4 and Tables S4 and S5.
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Mapping miRNA Binding Sites in Human BrainFurther characterization of the Ago2 brain clusters identified
thousands of putative miRNA:target gene pairs on the basis of
cluster sequence content and miRNA abundances. Computa-
tional site prediction with TargetScan and PITA was performed
on cluster sequences, and the top hits (up to ten per algorithm)
corresponding to abundant miRNAs (i.e., top 200 seeds) are
provided for each cluster (Table S3) (Grimson et al., 2007;
Kertesz et al., 2007). Enriched noncanonical sites for the
most highly abundant miRNAs (e.g., Let-7 7m9, miR-124
Bulge, miR-9 G:U, and miR-29 7m9) are also included. To
assess the functionality of these miRNA:target pairs, we
analyzed microarray data from studies evaluating the effects
of miRNA overexpression (ten experiments corresponding to
seven miRNAs) or inhibition (pooled depletion of 25 different
miRNAs) in cultured human cells (Hafner et al., 2010). As ex-
pected, miRNA overexpression resulted in the downregulation
of many Ago2 HITS-CLIP-identified targets for the respective
miRNA in each independent data set (Figures 4A and S4).
Overall, 30 UTR sites showed greater responsiveness than
those in coding regions (CDS; Figure 4B, top). This difference
in potency is consistent with prior studies, and more recent
data support that miRNA binding to CDS primarily inhibits
translation (Hausser et al., 2013). In miRNA inhibition studies,Neuron 81, 294–305targets identified by Ago2 HITS-CLIP
showed derepression (Figure 4B, bot-
tom), and, notably, the magnitude was
comparable to that observed for experi-
mentally validated miRNA:target inter-
actions recorded in miRTarBase (Hsu
et al., 2011).
Intersection of Human and Mouse
Ago HITS-CLIP Data
To gain insight into the conserved roles
of miRNAs in brain, we intersected ourdata set with orthologous regions corresponding to the mouse
brain Ago HITS-CLIP ternary map data (Chi et al., 2009). In the
latter, Ago HITS-CLIP was performed in developing mouse
brain (i.e., P13 neocortex). We identified 646 shared human
and mouse Ago HITS-CLIP regions, representing a significant
enrichment relative to background clusters (5-fold, Pearson’s
chi-square test, p < 2.2 3 1016; Figure 5A and Table S3).
Notably, 59% were in coding regions, providing a sizeable
resource for investigating the conserved functions of miRNAs
outside of 30 UTRs. Gene ontology analysis with the shared
target genes revealed an enrichment for synaptic localization
and functions (e.g., neuron projection, synapse assembly,
and neurotransmitter and ion transport), supporting a con-
served role of miRNAs as key regulators of gene expression
at sites distant from the transcriptional activities within the
nucleus (Figures 5B and 5C). Concurrently, Ago brain clusters
are enriched in genes producing transcripts that localize to
the synaptic neuropil (Cajigas et al., 2012) (Figure S5). We
also evaluated the regions corresponding to shared human
and mouse Ago brain clusters for the presence of TargetScan
predicted conserved miRNA binding sites. This analysis
produced 101 sites across 56 genes, many of these sites cor-
responding to brain-enriched miRNAs (Figure 5D)., January 22, 2014 ª2014 Elsevier Inc. 297
Figure 3. Positional Distribution and Conservation of Human Ago2 Brain Clusters
(A) The intragenic distribution of the 7153 human Ago2 brain clusters within mRNAs based on Ensembl gene annotations. The actual number of clusters in each
region is provided in parentheses.
(B) The actual nucleotide (blue line) and relative (red line) positional distribution of clusters within binned 30 UTR locations is shown. The inset graph (green line)
depicts the number of 30 UTRs by length for genes containing 30 UTR clusters, supporting that the observed decrease in clusters distant from 30 UTR ends (both
50 and 30) is not length dependent.
(C) The positional PhastCon scores within and near Ago2 brain clusters (centered on zero, median cluster size is 51 nt, shaded gray) are shown for all clusters or
non-CDS clusters. For the latter, Ago2 brain clusters located in CDS were removed in order to avoid a potential bias for coding regions to show increased
conservation, particularly for smaller exons that would be flanked by lesser conserved intronic sequences.
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Mapping miRNA Binding Sites in Human BrainIdentification of Clinically Relevant Ago2 Binding Sties
in Human Brain
Lastly, we explored the human Ago2 brain clusters for the pres-
ence of disease-relevant miRNA:target interactions. We focused
our initial efforts on miR-137, which was recently identified as a
‘‘hit’’ in a genome-wide association study among schizophrenia
patients and is also being investigated in bipolar disorder
(Schizophrenia Psychiatric Genome-Wide Association Study
(GWAS) Consortium, 2011; Whalley et al., 2012). Our data set
harbors 88 putative miR-137 sites (Table S6; based on canonical
TargetScan seeds), and 24 of these reside within schizophrenia-
related genes (SZGene database, n = 13) and/or genes having
correlated expression with prefrontal cortex abnormalities in
psychiatric patients (n = 16) (Allen et al., 2008; Kim and Webster,
2010). Notably, TCF4, a previously validated miR-137 target
(Kwon et al., 2013), was among these. Here, we tested seven
of these genes in order to determine their responsiveness to
miR-137. For this, 30 UTRs of the psychiatric disease-relevant
genes harboring miR-137 sites identified by our Ago2 HITS-
CLIP studies were cloned downstream of luciferase reporters
and tested in cell culture. Remarkably, all seven 30 UTR reporters
were suppressed by miR-137 treatment, relative to negative
control miRNA (30%–50% silencing; Figure 6A), providing
additional support (complementing the above microarray
analyses) for the functionality of the miRNA binding sites identi-
fied by our HITS-CLIP studies.
We further queried our data set for clinical relevance by search-
ing for Ago2 binding sites overlapping previously reported
disease-associated SNPs. This uncovered prospective clini-
cally-relevantmiRNA:target interactions ingenes linked tovarious
neuropsychiatric conditions (Table 1). With consideration that
such intersections may be due to random chance, we focused
this analysis on ‘‘hits’’ for which (1) the SNPs are predicted to alter
miRNA:target pairing within seed sites matching abundant brain
miRNAs (Figure S6) and (2) data exists to support relationships298 Neuron 81, 294–305, January 22, 2014 ª2014 Elsevier Inc.among the miRNAs, target genes, and disease. For example, in
the terminal exonof theTUBA1Agene,we identifiedanAgo2clus-
ter overlapping a lissencephaly-causing nonsynonymous muta-
tion, which imparts no obvious detriment to protein function
(Tianetal., 2010).Ourdata indicate that itwoulddisruptapotential
miR-124 seed, and the coincident expression of TUBA1A and
miR-124 in developing brain suggests that their interaction may
be required for proper corticogenesis (Coksaygan et al., 2006;
Maiorano and Mallamaci, 2009). We also detected a disease-
associated SNP predicted to enhance miR-124 binding within
an exonic Ago2 cluster in the IDS gene encoding iduronate
2-sulfatase. The prospect that this may augment the repression
of iduronate 2-sulfatase expression is interesting considering
that the mutation causes an enzyme deficiency resulting in an
attenuated form of Hunter syndrome (Sohn et al., 2012).
With respect to more prevalent neuropsychiatric conditions,
we identified a robust Ago2 cluster in exon 9 of the MAPT
gene encoding Tau. Others have shown that mutations in this
region may disrupt splicing inclusion of exon 10, which can
contribute to certain tauopathies, including Alzheimer’s disease
and frontotemporal dementia with Parkinsonism (Hasegawa
et al., 1999). MAPT also harbors a 30 UTR Ago2 cluster with a
predicted miR-128 binding site which overlaps a previously
described tauopathy-associated SNP (Gerrish et al., 2012).
These observations raise the intriguing possibility that
Ago2:miRNA interactions could contribute to tauopathies by
modulating the levels of pathogenic tau isoforms.
We also identified Ago2 binding sites overlaying SNPs pre-
dicted to disrupt miRNA seed sites in the 30 UTRs of SNCA
and SPP—genes with known involvement in neurological con-
ditions. SNCA encodes alpha-synuclein, a component of the
pathogenic aggregates observed in Parkinson’s disease, and
one of these SNPs (rs17016074) increases transcript levels
by >30% (Sotiriou et al., 2009), whereas the other resides within
a functional miR-153 binding site (Doxakis, 2010). Notably,
Figure 4. Ago2 HITS-CLIP Identifies Func-
tional miRNA:Target Gene Pairs
Functionality of miRNA:target gene pairs
identified by Ago2 HITS-CLIP was evaluated with
microarray data for gene expression changes
after miRNA overexpression or miRNA inhibition.
Cumulative fraction curves for miRNA:target
pairs (e.g., genes with 30 UTR or CDS Ago2
HITS-CLIP clusters or experimentally validated
miRNA:target genes recorded in miRTarBase;
each corresponding to the overexpressed or
inhibited miRNAs in the microarray experi-
ments) are plotted. Curve displacement to
the left or right, relative to background genes
(i.e., no site), indicates down- or upregulation,
respectively.
(A) Responsiveness of target genes in in-
dividual miRNA overexpression data sets
(NCBI GEO accession numbers: miR-124, GSM37601; miR-9, GSE33952; Let-7, GSE2918; and miR-29, GSE18713).
(B) Plots for summarized data from 10 miRNA overexpression studies (top) and a single data set for pooled miRNA inhibition (bottom) are shown.
See also Figure S4.
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Mapping miRNA Binding Sites in Human BrainSNCA duplications or triplications cause familial Parkinson’s
disease (Chartier-Harlin et al., 2004), and changes in alpha-
synuclein levels have been hypothesized to contribute to more
common forms of Parkinson’s. As for SPP1, this gene encodes
for secreted phosphoprotein 1, more commonly known as
osteopontin. Osteopontin increases to toxic levels in multiple
sclerosis and Crohn’s inflammatory bowel disease (Glas et al.,
2011; Niino et al., 2003), and the 30 UTR mutation, previously
implicated in both diseases, may contribute to this by disrupting
a potential binding site for miR-23b. Interestingly, miR-23b is
downregulated in and considered to be a broad suppressor of
autoimmune diseases, including lupus, rheumatoid arthritis,
and multiple sclerosis (Zhu et al., 2012).
As a first step toward evaluating the functional responses of
these disease-relevant miRNA:target interactions and the poten-
tial effects of the polymorphisms, we performed 30 UTR reporter
luciferase assays for the four miR-23 target genes in Table 1 (i.e.,
GATM, PDE8B, SPP1, and SNCA). All four showed a repressive
response to miR-23b treatment in cell culture, and, notably, a
significant impact of the SNP on silencing was observed for three
of the targets. These results validate the data set’s utility for
revealing clinically relevant information and warrant future
studies aimed at investigating these interactions in specific
brain-cell types. Furthermore, these and other examples in Table
1 corroborate the use of this brain miRNA:target interactome for
formulating hypotheses regarding the consequences of disease-
associated polymorphisms. To this end, we summarize informa-
tion for 916 common SNPs (minor allele frequency [MAF] > 1%)
present within the human Ago2 brain clusters (Table S7) to serve
as a resource for further investigation of polymorphisms thatmay
alter miRNA targeting and influence human disease phenotypes,
particularly for the many neurological conditions associated with
gene dosage abnormalities.
DISCUSSION
Data support that miRNAs contribute to protective and patho-
genic responses to disease; thus, identifying their targets inaffected tissues remains a crucial aspect of translational miRNA
research. Computational prediction has facilitated these efforts,
particularly for the study of canonical seed-based miRNA
binding sites. However, there is growing appreciation that bio-
logically relevant miRNA:target interactions can now be broadly
surveyed with the use of biochemical approaches, and recent
work has demonstrated that CLIP-based methods are inherently
better for identifying noncanonical miRNA binding sites (Chi
et al., 2012; Helwak et al., 2013). Therefore, we performed
Ago2 HITS-CLIP in order to generate a transcriptome-wide
map of miRNA binding sites in human brain, a tissue in which
miRNAs have been implicated in several diseases (Im and
Kenny, 2012). Our work revealed more than 7,000 Ago2 binding
sites, many of which harbor sequences corresponding to the
most abundant brain miRNAs. These data represent a valuable
resource for accelerating our understanding of miRNA functions
and how these effectors may interface with human diseases.
Here, focusing on the latter, we identify clinically relevant
miRNA:target interactions among our HITS-CLIP data and pre-
sent several exciting examples of how SNPs may contribute to
CNS pathologies through the modulation of miRNA activity.
Our luciferase validation studies demonstrate that disease-
relevant SNPs can influence silencingmediated bymiR-23b (Fig-
ure 6B). Interestingly, the GATM gene SNP tested showed the
most robust differential response, and the minor allele was
strongly repressed. GATM encodes for glycine amidinotransfer-
ase, a protein involved in creatine synthesis. Although the asso-
ciated GWAS study implicates this gene in chronic kidney
disease, rare GATMmutations have been shown to cause crea-
tine deficiencies in brain, leading to cognitive impairment (Item
et al., 2001). Further evaluation of whether the tested SNP affects
endogenous GATM levels in order to produce clinical pheno-
types will be interesting, particularly for individuals with minor
allele homozygosity.
We queried our data set for disease-relevant interactions
by identifying targets for the schizophrenia-related miRNA
miR-137. In addition to a previously validated interaction of
miR-137 with TCF4, our data support seven additional functionalNeuron 81, 294–305, January 22, 2014 ª2014 Elsevier Inc. 299
Figure 5. Intersection of Human and Mouse Brain Ago HITS-CLIP Data
(A) Venn diagram of the number of human Ago2 brain clusters overlapping with the mouse Ago HITS-CLIP brain data (**, ternary map data of miRNA binding sites
spanning 7 nt, further described in the Experimental Procedures) (Chi et al., 2009). The number of overlapping human background clusters (i.e., regions up- and
downstream of the Ago2 brain clusters; see the Supplemental Information) is provided as a control.
(B) Schematic depicting the processing of overlapping human (R50 nt) and mouse (7 nt) brain Ago HITS-CLIP clusters.
(C) Gene ontology analysis was performed with the genes that harbor ‘‘shared’’ clusters as input relative to all genes containing clusters as background.
(D) The overlapping regions were intersected with TargetScan-predicted conserved miRNA binding sites, and the top represented miRNAs (by number of sites)
are shown.
See also Figure S5.
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Mapping miRNA Binding Sites in Human Braintargets for miR-137 within genes associated with psychiatric
disease (Figure 6A). Intriguingly, there are six common SNPs
(>1% MAF) within five of these Ago2 clusters (residing in
CLDN11,GABRA1,NEFL,NRXN1, and RAPGEF5; refer to Table
S6), highlighting the prospect for future studies to evaluate the
effects of these SNPs on miR-137 activity. Altogether, these
analyses highlight the utility of this data set for identifying dis-
ease-relevant miRNA:target interactions, and future work may
help to elucidate additional targeting events involved in neurode-
generative or brain vasculature disease processes.
This resource will also be valuable for querying the basic bio-
logical functions of miRNAs. For instance, the field is currently
shifting focus to miRNA binding events in regions outside of 30
UTRs, and our data set includes hundreds to thousands of sites
in 50 UTRs, coding regions, and introns. Future work investi-
gating the functional relevance of these sites will be interesting,
particularly studies addressing whether intronic sites are
engaged by Ago2 in the nucleus or whether these represent re-
tained intronic sequences targeted in the cytoplasm. Another
exciting research avenue would be to test whether CDS-located
miRNA binding sites residing within alternatively spliced exons
confer isoform-specific silencing; indeed, a preliminary analysis
of our data set indicates the presence of nearly 400 clusters
within alternatively spliced cassette exons (data not shown).
CLIP data sets will also be useful for globally evaluating compet-
itive binding of miRNAs andRNA binding proteins throughout the
transcriptome. The possibility of such events involving negative
and positive regulators provides attractive means for potent
switches in gene regulation mediated at the posttranscriptional
level. Alternatively, similar biological switches can be achieved
through feedback loops involving miRNAs and transcription
factors (Iwama, 2013; Kim et al., 2007), and our Ago2 HITS-300 Neuron 81, 294–305, January 22, 2014 ª2014 Elsevier Inc.CLIP targets include hundreds of transcription factor mRNAs,
providing a key resource for ongoing investigations of these
types of regulatory circuits.
Future analyses of disease- and biologically relevant
miRNA:target interactions in brain could be prioritized by
focusing on conserved sites identified in both mouse and human
Ago HITS-CLIP studies. Although these data sets are signifi-
cantly enriched for shared sites, the proportion of nonoverlap-
ping sites is notably larger (Figure 5A). This could be the result
of obvious differences between mouse and human brains and/
or the varying transcriptomes and miRNA profiles in developing
(mouse samples) versus adult (human samples) brains. Alterna-
tively, the mouse data were generated with a pan-Ago antibody,
whereas the antibody we employed was specific to Ago2. How-
ever, several prior reports have noted that, for the most part,
endogenous miRNAs are equivalently sorted into Ago1 and
Ago2 (Dueck et al., 2012). Alternatively, disparities between the
human and mouse data could reflect the methods and criteria
used in peak-calling procedures, given that the mouse Ago
ternary map includes many miRNA binding sites with minimal
read evidence across few biological replicates. Inevitably, addi-
tional studies will be required for determining whether any or
all of these factors contribute to the observed discrepancies or
whether miRNA targeting in brain can indeed diverge so greatly
across species.
Overall, our studies and the accompanying data sets provide a
foundation for the further characterization of miRNA:target inter-
actions throughout other brain structures and across normal and
diseased human tissues. Expansion into additional brain regions
(e.g., midbrain and hindbrain) as well as nonhuman primates will
help to clarify how miRNAs contribute spatiotemporally and
evolutionarily in higher-order brain and will complement the
Figure 6. Functional Responsiveness of Dis-
ease-Relevant miRNA Binding Sites
Plasmids (10 ng) coexpressing Firefly luciferase
(normalizer) and Renilla luciferase reporters
harboring 30 UTRs corresponding to the indicated
genes were cotransfected along with synthetic pre-
miRs (50 uM) into HEK 293 cells. Dual luciferase
assays were performed at 24 hr posttransfection,
and Renilla/Firefly ratios were normalized to the
pre-miR-Neg1 treatment for each 30 UTR construct.
CTRL is the ‘‘empty’’ parental plasmid into which 30
UTRs were cloned.
(A) Silencing activity of miR-137 on schizophrenia-
related gene 30 UTRs harboring miR-137 sites
identified by Ago2 CLIP-seq.
(B) Effects of disease-relevant SNPs predicted to
alter miR-23 binding sites (refer to Table 1 and
Figure S6) on 30 UTR silencing mediated by pre-
miR-23b. Alleles predicted to be silenced are
shown in blue, and alleles that disrupt seed pairing
are shown in red. Major and minor alleles are
denoted by ‘‘>’’ or ‘‘<’’ symbols, respectively. In
both panels, each bar depicts the mean ± SEM for
nR 3 biological replicates for each treatment. Two-
tailed pairwise Student’s t tests for the indicated
comparisons were performed, and p values are
provided. n.s., not significant.
See also Figure S6 and Table S6.
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of primate species (Bernard et al., 2012; Somel et al., 2013).EXPERIMENTAL PROCEDURES
Samples
Postmortem human brain samples were obtained from Juan Troncoso
(Brain Resource Center at Johns Hopkins University School of Medicine)
with informed consent from families. Gray matter tissues were harvested
from the motor cortex (Brodmann’s area 4) and cingulate gyrus and stored
at 80*C until use. Detailed sample information is provided in Table S1.
Ago2 HITS-CLIP
CLIP was performed as previously described (Chi et al., 2009) with modifica-
tions. Samples (60 mg) of human postmortem brain tissue were triturated
in cold PBS, UV crosslinked, lysed, and treated with DNase and a low concen-
tration of RNase. Immunoprecipitation was performed by incubating lysed
samples with Protein A Dynabeads (Invitrogen) complexed with anti-Ago2-
3148 (Grey et al., 2010). Then, beads were washed, treated with polynucleo-
tide kinase 32P-g-ATP in order to 50-end label the associated RNAs, and
washed again. 50 linker ligation was performed with a PAGE-purified DNA-
RNA hybrid linker containing 50 Amino Modifier C6, RNA bases (underlined)
and ambiguous bases (Ns): 50-(5AmMC6)-CCTCTCTAUGGGCAGUCGGU
GAUNNNNG-30. Then, samples were treated with calf intestinal alkaline phos-
phatase in order to remove 30 phosphates. Immunoprecipitated complexes
were resolved on a NuPAGE Novex 3–8% Tris-Acetate Gel with Tris-Acetate
running buffer as per the manufacturer’s instructions (Invitrogen). Products
were transferred to BA-85 nitrocellulose (Whatman) with the Mini-PROTEAN
3 cell and Mini Trans-Blot module (Bio-Rad), and film autoradiography was
performed. The bands corresponding to Ago2 complexed with miRNAs
(110 kDa), and Ago2:miRNA:target complexes (130 kDa) were cut, placed
in 1.5 ml Eppendorf tubes, and treated with proteinase K (Qiagen). RNAs were
extracted with phenol and chloroform and overnight precipitation in 3M
NaOAc (pH 5.2) in a 1:1 EtOH:isopropanol solution, and ligated to a PAGE-
purified 30 RNA linker (note that the 30 RNA linker was 50 phophorylated and
30 puromycin blocked; 50-P-GUUACGCUCGCCGUAGAGG-Pmn-30). Afterphenol and chloroform extraction and precipitation, samples were subjected
to RT-PCR with a reverse primer (50-AGTTCAGACGTGTGCTCTTCCG
ATCCTCTACGGCGAGCGTAAC-30) for the RT reaction followed by PCR
with the reverse and forward(50-CCTCTCTATGGGCAGTCGGTGAT-30)
primers (95C for 2 min followed by 25–30 cycles of 95C for 20 s, 59C for
25 s, 72C for 20 s, and lastly a 5 min incubation at 72C). Products corre-
sponding to miRNAs and target RNA tags were PAGE purified with traditional
methods and subjected to a second round of PCR in the presence of custom
Illumina Hi-Seq fusion primers (see below; 95C for 2 min followed by 10–15
cycles of 95C for 20 s, 61C for 25 s, 72C for 30 s, and lastly a 5 min incuba-
tion at 72C). The primers were ILMN-F1 DNA primer (50-AATGATACGGC
GACCACCGACAGGTCCTCTCTATGGGCAGTCGGTGAT-30) and an example
of the ILMN barcode primer (ILMN-BCn; barcode underlined, 50-CAAGCA
GAAGACGGCATACGACGTGATGTGACTGGAGTTCAGACGTGTGCTC
TTCCGATC-30). Eight barcodes were used: (1) CGTGAT, (2) ACATCG, (3)
GCCTAA, (4) TGGTCA, (5) CACTGT, (6) ATTGGC, (7) GATCTG, and (8)
TCAAGT. Products were PAGE purified, and a quality assessment of the
Ago2 HITS-CLIP libraries was performed by the University of IowaDNA Facility
with the High Sensitivity DNA Assay on the Agilent Bioanalyzer DNA-1000.
Library concentration was measured with a KAPA Library Quantification Kit
for Illumina (Kapa Biosystems) according to manufacturer’s instructions.
Libraries were concentrated (by speed-vac) or diluted to 10 nM as needed.
High-throughput sequencing was carried out by the University of Illinois, Roy
J. Carver Biotechnology Center on the Illumina Hi-Seq 2000. Libraries were
pooled in order to allow sequencing of four samples per lane (miRNAs and
target RNA tags for each sample; eight total barcodes). A 9:1 ratio of
tags:miRNA libraries was used, and pooled libraries (10 nM) were submitted
to the sequencing facility along with a custom Read1 primer (100 uM; custom
Read1 sequencing primer [DNA], 50-CAGGTCCTCTCTATGGGCAGTCGG
TGAT-30). We obtained 75–100 nt reads with Read1, and the barcode was
sequenced by standard means.
Western Blot
Protein sampled during the CLIP procedure was separated on a NuPAGE
Novex 3–8% Tris-Acetate Gel (Invitrogen) before being transferred to a
0.45 mm polyvinylidene fluoride membrane (Millipore). The membrane was
blocked with 2% milk in 13 PBS with 0.05% Tween 20. Mouse anti-Ago2Neuron 81, 294–305, January 22, 2014 ª2014 Elsevier Inc. 301
Table 1. Summary of Disease-Relevant SNPs in Human Ago2 Brain Clusters
Gene Disease SNP ID Alleles (MAFa) Effect of Minor Allele Comments Sourceb
TUBA1A Lissencephaly rs137853044 G/A (rare) Disrupts miR-124 seed R402H substitution may be
tolerated
HGMD
IDS Hunter syndrome rs141720810 C/G (rare) Enhances mIR-124 site Disease caused by enzyme
deficiency
HGMD
MAPT Tauopathies rs17652121 T/C (11%) Disrupts miR-181 seed SNP may alter splicing of
exon 10
GWAS-LD
rs9468 T/C (7.8%) Disrupts miR-128 seed SNP defines H2 haplotype Gerrish et al., 2012
SNCA Parkinson’s rs17016074 C/T (4.4%) Disrupts miR-23 seed SNP alters transcript stability HGMD










rs6757825 G/A (13.3%) Disrupts miR-22 seed Earlier onset may be
cholesterol related
GWAS-LD
PUM2 ADHD rs6669 G/A (3.6%) Disrupts miR-377 seed Nearby rs1043419 assoc.
with ADHD
miRdSNP
PDLIM5 Schizophrenia rs12294 C/T/G (32%,
0.5%)
Disrupts miR-19 seed Elevated PDLIM5 assoc.
with disease
miRdSNP
PDE8B Alzheimer’s rs1580 T/A (rarec) Disrupts miR-23 seed Elevated PDE8B assoc.
with disease
miRdSNP
PCSK1 Obesity rs6235 G/C (38%) Disrupts miR-92 seed Potential miR-9 site within
10 nt
GWAS
CELSR2 Cholesterol rs629301 T/G (22%) Creates miR-10 seed CELSR2 may play a role in
cholesterol efflux
GWAS-LD
GATM Kidney disease rs17618637 G/A (5%) Enhances miR-23 seed Disease caused by enzyme
deficiency
GWAS-LD
Refer to Figure S6A for miRNA:target base pairing diagrams showing the positions of the respective SNPs. Refer to Figure S6B for reproducibility of
Ago2 HITS-CLIP data within regions encompassing these SNPs.
aMAF, minor allele frequency; MS, multiple sclerosis; and IBD, inflammatory bowel disease.
bHGMD, Human Gene Mutation Database. GWAS-LD refers to SNPs (MAF>5%) in linkage disequilibrium (R2=1) with GWAS SNPs.
cPDE8B SNP (rs1580) was originally reported as having a 16% MAF. During the revision of this manuscript, dbSNP135 updated the MAF to <1%.
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Mapping miRNA Binding Sites in Human Brain(Wako Pure Chemicals Industries) diluted 1:2,000 in blocking buffer was added
and incubated overnight at 4C followed by horseradish-peroxidase-
conjugated goat anti-mouse (Jackson ImmunoResearch) diluted 1:10,000 in
blocking buffer. Ago2 protein was detected by ECL Plus substrate (Amersham
Biosciences) and film.
Preprocessing and Mapping of Ago2 HITS-CLIP Tags
We removed the first 5 nt, which corresponded to the 30 end of the 50 linker,
from the 50 end of reads. Then, we scanned the reads from 50 end to 30 end
by the adaptor sequence (GTTACGCTCGCCGTAGAGG), allowing up to two
mismatches. Because it is possible that the adaptor that is attached to 30
end of the read is not completely sequenced, we also scanned the 30 end of
reads that require at least 10 nt by the 50 end of adaptor, allowing up to two
mismatches. After adaptor trimming, we excluded reads with length less
than 10 nt from downstream analysis. Then, adaptor-trimmed mRNA tags
were mapped to the human genome (hg19) with Bowtie (Langmead et al.,
2009), allowing up to two mismatches. Gene coordinates were downloaded
from Ensembl (version 57).
Estimation of miR Expression Levels
We downloaded the human miRNA sequences from miRBase (release 18)
(Kozomara and Griffiths-Jones, 2011) and merged redundant miRNA
sequences from the same miRNA family. Then, we used Bowtie to map the
miRNA tags to themiRBase, allowing up to onemismatch. ThemiRNA expres-
sion levels are quantified as the number of reads mapped to individual miRNAs302 Neuron 81, 294–305, January 22, 2014 ª2014 Elsevier Inc.normalized by the total number of mapped reads in miRBase. The expression
levels fromdifferent sampleswere further normalized by quantile normalization
in order to control for batch effect.
Peak Calling by Zero-Truncated Negative Binomial Model
We used the zero-truncated negative binomial model (ZTNB) to measure the
significance of read coverage height for each mapped position (Uren et al.,
2012). For each gene in a given sample, we assume that the height of each
position follows the Poisson distribution, yi Poisson (li), yi > 0. li is the
expected height for position 1, and it is a random variable following a gamma
distribution, li Gamma (1/a, a), where a is the overdispersion parameter.
If a = 0, then it is reduced to Poisson. The ZTNB distribution has density










where mi = li (as in Poisson).
The a parameter is estimated by maximum likelihood function with
numerical method. For each height (Hi), the p value (Pi) is calculated by
summing the probabilities for finding Hi, or higher height. The calculation is
performed by R packages MASS and pscl.
To call HITS-CLIP peaks with information from multiple replicates, we used
Fisher’s method to combine p values of replicates. For each position, we com-
bined the p values from all biological replicates into one test statistic (c2) using
the formula
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where pj is the p value for the j
th replicates. c2 has a chi-square distribution
with 2k degrees of freedom, where k is the number of replicates. The combined
p value for each position was adjusted by Bonferroni correction in order to
account for multiple hypothesis testing.
Identification of Statistically Significant Ago2 Brain Clusters
We used Bonferroni adjusted p value < 0.05 as the cutoff in order to define
statistically significant positions. Then, we merged those significant positions
into continuous regions for any positions within 60 nt of each other. Given that
the average Ago-mRNA footprint is 45–62 nt (Chi et al., 2009), we extended the
continuous regions with length less than 50 nt to 50 or 51 nt symmetrically from
the 50 and 30 ends. We defined those regions as Ago2 brain clusters. Further-
more, we defined the specific positions of Ago2 brain clusters with respect to
annotated gene structures. The gene structure information (e.g., exon, intron,
CDS, and UTRs) was downloaded from Ensembl (version 57) in order to deter-
mine the intragenic locations of the Ago2 brain clusters. Intragenic clusters
with ambiguous locations (i.e., those falling in more than one category; for
example, both CDS and 30 UTR) were assigned positions on the basis of the
prioritization scheme (30 UTR > CDS > 50 UTR > intron) for the data shown in
Figure 3A. As an alternative, we also assigned ambiguous clusters partial
values (e.g., 0.5 cluster to CDS and 0.5 cluster to 30 UTR). This yielded the
following positional distributions: 3% 50 UTR, 38% CDS, 33% 30 UTR, 23%
intron, and 3% other. The values for this latter scoring scheme are provided
in the cluster summary (Table S3).
Correlation of Ago2-Associated RNAs across Samples
Wiggle files were generated with the use of an in-house program to determine
the read coverage at each genomic position for each sample data set on
a per-genomic-strand basis. Wiggle files for plus and minus strands for each
sample were combined across all genomic intervals. Overlapping intervals
between the two files were merged by taking the maximum height at each
genomic position. Then, all pair-wise correlations were performed with the
wigCorrelate script available from the UCSC Genome Browser (Rhead et al.,
2010).
PhastCon Score
Positional conservation within the human Ago2 brain clusters was evaluated
with the Conservation Plot (version 1.0.0) tool available as part of the Cistrome
Analysis Pipeline Module (Liu et al., 2011). A window size of 600 nt was used.
Motif Analysis
The Regulatory Sequence Analysis Tools (RSAT) peak motifs package was
used to analyze the Ago2 brain cluster sequences by inputting 100 nt peak
sequences centered on the clusters and using default parameters to identify
ten motifs per algorithm on single strands (Thomas-Chollier et al., 2012).
Data from this analysis was used for Figures 2A and S2B. As an alternative,
we also performed motif analysis in order to identify enriched motifs within
Ago2 brain clusters relative to background clusters. For the latter, we selected
upstream (100 nt cluster_length, 100 nt) and downstream (100 nt + clus-
ter_length, +100 nt) coordinates and excluded regions overlapping with Ago2
brain cluster regions. We implemented a sliding window scan (window size = 7
nt) of each region (brain clusters or background) with a 1 nt increment in order
to identify the incidences of all possible heptamers, including miRNA seeds.
Enrichment data for all possible heptamers was used to generate Figure S3
and Table S4. To determine the enrichment of motifs corresponding to
miRNAs, we summarized the data matching 7m8 and 7A1 site types for all
known miRNA seeds (Grimson et al., 2007). The p value for any given miRNA
seed was calculated from the number of windows that matched miRNA seeds
in all Ago2 brain cluster and background regions with a Fisher’s exact test.
The p values were transformed to FDRs with the Benjamini-Hochberg pro-
cedure (Benjamini and Hochberg, 1995). Summarized seed data were used
to produce Figure 2C and Table S5.Functional Validation of miRNA:Target Gene Pairs
Microarray data for the indicated miRNA overexpression and inhibition studies
were obtained from the NCBI Gene Expression Omnibus (GEO). Data were
processed with GEO2R or Partek Genomics Suite (Partek) in order to deter-
mine log2 fold changes in gene expression between experimental and control
conditions. For miRNA overexpression studies, the cumulative fractions of
Ago2 HITS-CLIP target genes (with 30 UTR- or CDS-located clusters harboring
the relevant miRNA seed sites) and background genes (i.e., no site) were
generated for each of the 10 miRNA overexpression microarray data sets
(individual plots shown in Figures 4A and S4). Data for these analyses were
grouped by discrete intervals (0.01 log2 fold-change increments). The data
for all ten experiments were summarized by averaging the cumulative fraction
values for targets and background sets at each interval (Figure 4B, top). For the
miRNA inhibition study, Hafner et al. (2010) performed a pooled depletion of 25
highly expressed miRNAs in human embryonic kidney (HEK) 293 cells. Among
these, seven corresponded to highly abundant brain miRNAs present in our
data, including the following seed families: Let-7, miR-15/16, miR-30, miR-
101, miR-103/107, miR-124, and miR-27. Genes containing 30 UTR-located
Ago2 HITS-CLIP clusters harboring sites matching any of these seven miRNA
seeds were used for this analysis (Figure 4B, bottom, ‘‘CLIP 30 UTR’’), as were
experimentally validated target genes for any of these seven miRNAs, on the
basis of miRTarBase entries (Hsu et al., 2011).
For luciferase-based validation studies, 30 UTRs for the indicated target
genes were PCR amplified from human genomic DNA (isolated from HeLa
and HEK 293 cells) with the DNA primers provided in Table S8. Products
were digested with XhoI and NotI and ligated into these same sites within the
dual luciferase expression plasmid psiCheck2 (Promega). This positions the
30 UTRs downstream of Renilla luciferase, creating an experimental reporter,
whereas the Firefly luciferase serves as the normalizing control. Site-directed
mutagenesis was performed with standard methods in order to engineer the
relevant SNP alleles into 30 UTR reporter constructs. HEK 293 cells grown in
24-well plates were cotransfected in triplicate with 10 ng of luciferase reporter
plasmids and 50 uM of commercially available synthetic pre-miRNAs corre-
sponding tomiR-137,miR-23b,or anegativecontrol (miR-Neg1). Transfections
were performed with Lipofectamine 2000 (Invitrogen), and Firefly and Renilla
luciferase activities were assessed at 24 hr posttransfection with the Dual-
Glo Luciferase Assay System (Promega) per the manufacturer’s instructions.
Luminescent readings were measured for each sample in duplicate using a
GloMaxMicroplate Reader (Promega), and results were calculated as the quo-
tient of Renilla/Firefly luciferase activities with subsequent normalization to the
pre-miR-Neg1 control for each 30 UTR tested. Biological replicates were
increased to n = 6 by repeating the transfections and downstream analyses.
Intersection to Mouse Ago HITS-CLIP Data
For the intersection of human Ago2 brain clusters with mouse Ago HITS-CLIP
data, we used the downloadable ternary map data from http://ago.rockefeller.
edu/AgoTernaryTable_mm9.txt/ (Chi et al., 2009) and converted the coordi-
nates to human hg19 with the Galaxy lift-over function (Goecks et al., 2010).
Note that the mouse Ago ternary map consists of all sites (i.e., uncurated in
terms of robustness) identified by Ago HITS-CLIP in P13 mouse neocortex
(refer to Chi et al., 2009, for a description).
Gene Ontology Analysis
Gene ontology analysis was performed with theGOrilla web server (Eden et al.,
2009). Official gene symbols for genes containing human and mouse shared
Ago brain clusters were input as the ‘‘target set,’’ and genes containing human
Ago2 brain clusters were input as ‘‘background set’’ in order to control for bias
of HITS-CLIP approaches toward higher expressed transcripts.
Evaluation of SNPs
Genomic coordinates of human Ago2 brain clusters were intersected with
coordinates of GWAS SNPs (Hindorff et al., 2009) and accompanying SNPs
in complete linkage disequilibrium (R2 = 1) having minor allele frequencies >
5% (dbSNP 135). Additional disease-relevant SNPs or mutations were curated
from RegulomeDB (Boyle et al., 2012), miRdSNP (Bruno et al., 2012), Human
Gene Mutation Database (Stenson et al., 2009), literature review, and the
UCSC Genome Browser (Rhead et al., 2010). Note that rs9468 andNeuron 81, 294–305, January 22, 2014 ª2014 Elsevier Inc. 303
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Mapping miRNA Binding Sites in Human Brainrs629301 were identified in Ago2 brain clusters with Bonferroni adjusted
p value < 25%, while all others overlap with Bonferroni adjusted p value <
5% clusters. Putative miRNA target sites within human Ago2 brain clusters en-
compassing disease-relevant SNPs were identified with TargetScan (Grimson
et al., 2007), PITA (Kertesz et al., 2007), RegRNA (Huang et al., 2006), or
miRdSNP (Bruno et al., 2012), and miRNA:target hybridization was evaluated
with the RNAhybrid web server (Kru¨ger and Rehmsmeier, 2006).
ACCESSION NUMBERS
Relevant data sets, including raw data, have been deposited in the NCBI Gene
Expression Omnibus under accession number GSE52084.
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